Business Context and Reporting Period
This Form 8-K was filed by OvaScience, Inc. on June 21, 2017. The filing reports a strategic restructuring and significant changes to executive leadership. The Company is a biotechnology firm focused on fertility treatments, specifically OvaTure (preclinical) and OvaPrime (clinical). The filing notes the discontinuation of the AUGMENT treatment outside of North America.
Key Financial Metrics and Liquidity
The filing does not provide specific revenue, profit, or historical cash flow figures. However, it outlines the following financial impacts and liquidity outlook:
- Restructuring Costs: The Company anticipates one-time cash items of $3.5 million to $4.5 million related to the June 2017 restructuring, expected to be substantially completed in the third quarter of 2017.
- Liquidity Runway: Following the restructuring and workforce reduction, the Company expects sufficient funds to support its revised operating plan into the first quarter of 2020 without additional financing.
- Executive Compensation:
- Christopher A. Kroeger (New CEO): $550,000 annual base salary; up to 60% discretionary bonus; 1,783,106 stock options.
- Michelle Dipp (Outgoing Executive Chair): $241,667 for remainder of 2017; $250,000 for 2018; 175,000 stock options.
- Jonathan Gillis (New VP Finance): $250,000 annual base salary; up to 35% discretionary bonus; 30,000 stock options.
- Christophe Couturier (Outgoing CFO): Severance of six months' base salary, $105,000 pro rata bonus, and $50,000 retention bonus.
Material Changes
The filing details several material changes effective June 21, 2017:
- Workforce Reduction: The Company will reduce its workforce by approximately 50% to align with strategic priorities.
- Portfolio Focus: Discontinuation of efforts related to the AUGMENT treatment outside of North America. Focus is now solely on OvaTure and OvaPrime.
- Leadership Transition:
- Christopher A. Kroeger appointed CEO Elect, effective immediately, with full CEO duties starting September 1, 2017.
- Michelle Dipp will step down as Executive Chair and Acting President on September 1, 2017, transitioning to an advisory role.
- Christophe Couturier is stepping down as CFO; Jonathan Gillis is promoted to VP Finance and Principal Financial Officer.
Guidance, Outlook, and Risks
Operational Milestones (2019):
- OvaPrime: Complete embryo transfers by Q1 2019; initial safety data readout by Q1 2019; all potential births by end of 2019; initial readout of embryo transfers by end of 2019.
- OvaTure: Bovine live birth by Q1 2019; six-month follow-up by Q3 2019; submission for human regulatory approval by Q2 2019.
Risks and Contingencies:
- The science underlying the treatments is unproven.
- There is no guarantee of regulatory approval or successful commercialization.
- Timelines for development and commercialization may differ materially from expectations.
- The Company disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the actual cash outflow for the restructuring against the estimated $3.5 million to $4.5 million range in the Q3 2017 financials.
- Confirm the Company's cash balance and burn rate to validate the runway into Q1 2020.
- Monitor the transition of leadership, specifically the handover from Dr. Dipp to Dr. Kroeger on September 1, 2017.
- Track progress on the specific 2019 clinical milestones for OvaPrime and OvaTure as outlined in the filing.
- Review the impact of the 50% workforce reduction on the Company's ability to execute its revised operating plan.